Roche set to conquer top market

All new listings considered at the PBAC's May intracycle meeting were recommended, including Roche's yet to be TGA approved eye drug Vabysmo, which is expected to hit blockbuster status.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here